Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Co.'s lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. We show 22 historical shares outstanding datapoints in our coverage of SLRX's shares outstanding history.
Understanding the changing numbers of SLRX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SLRX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SLRX by allowing them to research SLRX shares outstanding history
as well as any other stock in our coverage universe. |
Free SLRX Email Alerts:
Video: Shares Outstanding Importance
